News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AbbVie (ABBV) Beats Forecast as Humira Sales Surge


10/28/2013 6:50:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AbbVie Inc (ABBV.N) on Friday reported stronger-than-expected results for the third quarter, as booming sales of its Humira arthritis treatment and Synthroid thyroid replacement drug more than offset lower demand for other medicines. Shares of the drugmaker, which was split off at the beginning of the year from Abbott Laboratories Inc (ABT.N), rose 2.4 percent. Humira, a treatment for rheumatoid arthritis, psoriasis, Crohn's disease and other conditions, is the world's top-selling prescription drug.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at News Release
Read at Seeking Alpha


comments powered by Disqus
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES